BioCurex Signs Collaboration Agreement with Goshen Cancer Center
BioCurex Inc. announced that it has initiated a collaboration with the Center for Cancer Care in Goshen, Indiana, for developing and evaluating its RECAF(tm) technology. The collaboration with Biocurex and the Center for Cancer Care is long term and will consist of three phases: The first one will continue and expand the applications of BioCurex's serum and biopsy tests using RECAF(tm). The second phase will focus on imaging applications using RECAF(tm) to detect the location of cancerous tumors in the body. The third phase includes clinical trials in which RECAF(tm) will be used as a way to specifically deliver therapeutic agents to destroy the cancer cells with minimal damage to normal tissues. The third phase is contingent to the previous development of animal and culture models demonstrating the benefits of RECAF for targeting cancer cells.
A cancer marker allows one to distinguish cancer cells from non-cancerous cells. RECAF(tm) is a cancer marker exclusively developed and patented by BioCurex, Inc. Cancer markers most widely used in the detection and treatment of cancer include AFP, CEA, PSA and Ca125. An ideal cancer marker is a molecule present in all cancer cells but not in normal or benign tumor cells. RECAF(tm) could become the one cancer marker suitable to detect all cancer types. The potential benefit RECAF(tm) offers to patients is a superior diagnostic tool and a new way to deliver targeted therapy.
Other news from the department science
